NEW YORK (GenomeWeb News) - Laboratory Corporation of America will use Affymetrix’s genotyping tools in a molecular cytogenetic service it will offer to US researchers, Affy said today.
Under the agreement, LabCorp will use Affy’s GeneChip technology in an offering that its customers can use to “correlate deletions, gains and other chromosomal rearrangements with congenital diseases such as autism, mental retardation and development delay in children,” the company said.
Using the GeneChip will allow LabCorp to offer researchers enhanced “resolution for the detection of the etiology of mental retardation, developmental delay, autism and other clinically significant changes,” LabCorp Executive VP, CSO, and Medical Director Myla Lai-Goldman, said in a statement.
Financial terms of the agreement were not released.